Everolimus to treat aggressive retinal astrocytic hamartoma in tuberous sclerosis complex.
Publication
, Journal Article
Nallasamy, N; Seider, MI; Gururangan, S; Mruthyunjaya, P
Published in: Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
August 2017
Retinal astrocytic hamartomas (RAH) are the most frequent ocular manifestation of tuberous sclerosis complex and are usually indolent, requiring only observation. We report an aggressive RAH subtype in a child unresponsive to anti-VEGF and laser therapy. Treatment with systemic everolimus was well-tolerated and significantly reduced ocular (and nonocular) tumor size and fluid exudation.
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
DOI
EISSN
1528-3933
ISSN
1091-8531
Publication Date
August 2017
Volume
21
Issue
4
Start / End Page
328 / 331
Related Subject Headings
- Tuberous Sclerosis
- TOR Serine-Threonine Kinases
- Retinal Diseases
- Ophthalmology & Optometry
- Male
- Infant
- Immunosuppressive Agents
- Humans
- Everolimus
- Drug Administration Schedule
Citation
APA
Chicago
ICMJE
MLA
NLM
Nallasamy, N., Seider, M. I., Gururangan, S., & Mruthyunjaya, P. (2017). Everolimus to treat aggressive retinal astrocytic hamartoma in tuberous sclerosis complex. Journal of AAPOS : The Official Publication of the American Association for Pediatric Ophthalmology and Strabismus, 21(4), 328–331. https://doi.org/10.1016/j.jaapos.2017.04.012
Nallasamy, Nambi, Michael I. Seider, Sridharan Gururangan, and Prithvi Mruthyunjaya. “Everolimus to treat aggressive retinal astrocytic hamartoma in tuberous sclerosis complex.” Journal of AAPOS : The Official Publication of the American Association for Pediatric Ophthalmology and Strabismus 21, no. 4 (August 2017): 328–31. https://doi.org/10.1016/j.jaapos.2017.04.012.
Nallasamy N, Seider MI, Gururangan S, Mruthyunjaya P. Everolimus to treat aggressive retinal astrocytic hamartoma in tuberous sclerosis complex. Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus. 2017 Aug;21(4):328–31.
Nallasamy, Nambi, et al. “Everolimus to treat aggressive retinal astrocytic hamartoma in tuberous sclerosis complex.” Journal of AAPOS : The Official Publication of the American Association for Pediatric Ophthalmology and Strabismus, vol. 21, no. 4, Aug. 2017, pp. 328–31. Epmc, doi:10.1016/j.jaapos.2017.04.012.
Nallasamy N, Seider MI, Gururangan S, Mruthyunjaya P. Everolimus to treat aggressive retinal astrocytic hamartoma in tuberous sclerosis complex. Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus. 2017 Aug;21(4):328–331.
Published In
Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus
DOI
EISSN
1528-3933
ISSN
1091-8531
Publication Date
August 2017
Volume
21
Issue
4
Start / End Page
328 / 331
Related Subject Headings
- Tuberous Sclerosis
- TOR Serine-Threonine Kinases
- Retinal Diseases
- Ophthalmology & Optometry
- Male
- Infant
- Immunosuppressive Agents
- Humans
- Everolimus
- Drug Administration Schedule